7.2 Hemolytic Disease & Neonatal Hematologic Disorders
Key Takeaways
- Isoimmune hemolytic disease encompasses ABO incompatibility (maternal blood group O, infant A or B; frequently affects first pregnancy; weakly positive DAT, spherocytes, mild-to-moderate jaundice) and Rh alloimmunization (Rh-negative mother, anti-D IgG; spares first pregnancy unless sensitized; strongly positive DAT, severe anemia, erythroblastosis fetalis, hydrops fetalis); RhoGAM prophylaxis (300 mcg at 28 weeks and within 72 hours postpartum) prevents Rh sensitization.
- Intravenous Immunoglobulin (IVIG 0.5–1.0 g/kg over 2 hours) blocks reticuloendothelial Fc receptors to arrest active hemolysis in isoimmune disease, whereas Double-Volume Exchange Transfusion (160–170 mL/kg term, 160–200 mL/kg preterm) clears 85% of sensitized erythrocytes and halves TSB for infants meeting exchange thresholds or displaying encephalopathy.
- Exchange transfusion carries major multi-system risks requiring intensive monitoring: hypocalcemia (citrate-mediated calcium binding; keep 10% calcium gluconate available), hyperkalemia (stored RBC hemolysis; use fresh blood <5–7 days old), rebound hypoglycemia (post-procedure insulin surge), thrombocytopenia, and necrotizing enterocolitis (strict NPO during and for 24 hours post-procedure).
- Neonatal polycythemia is defined by a central venous hematocrit ≥65% (never diagnosed on capillary blood alone) producing hyperviscosity, microvascular thrombosis, hypoglycemia, and cyanosis; symptomatic neonates or those with venous Hct ≥70% require Partial Exchange Transfusion with 0.9% Normal Saline to reduce hematocrit to 55%.
- Neonatal Alloimmune Thrombocytopenia (NAIT) results from maternal anti-HPA-1a alloantibodies destroying fetal platelets, uniquely presenting in 50% of first pregnancies with profound thrombocytopenia (<20,000/μL) and high intraventricular hemorrhage risk in an otherwise healthy infant of a mother with a normal platelet count; managed with washed maternal or HPA-negative platelets and IVIG.
Last updated: August 2026
7.2 Hemolytic Disease & Neonatal Hematologic Disorders
Neonatal hematologic disorders range from acute isoimmune-mediated erythrocyte destruction to life-threatening platelet consumption and microvascular hyperviscosity. Prompt identification of hemolytic disease, rapid stabilization of severe anemia, meticulous execution of exchange transfusions, and accurate calculation of partial exchange volume for polycythemia are essential core competencies for neonatal nurses caring for vulnerable newborns.
1. Isoimmune Hemolytic Disease: ABO Incompatibility & Rh Alloimmunization
Isoimmune hemolytic disease occurs when maternal immunoglobulin G (IgG) antibodies directed against fetal red blood cell (RBC) surface antigens cross the placenta into the fetal circulation, binding to fetal erythrocytes and causing accelerated reticuloendothelial destruction.
Comparison: ABO Incompatibility vs. Rh (Anti-D) Alloimmunization
| Clinical Parameter | ABO Incompatibility | Rh (Anti-D) Alloimmunization | Minor Blood Group Incompatibility |
|---|---|---|---|
| Maternal Blood Type | Group O (possesses anti-A and anti-B IgG) | Rh-Negative (D-negative) | Antigen negative (e.g., Kell, Duffy, Kidd) |
| Infant Blood Type | Group A or Group B (rarely AB) | Rh-Positive (D-positive) | Antigen positive (e.g., Kell [$K_1$], $Fy^a$, $Jk^a$) |
| First Pregnancy Involvement | Yes (40% to 50% of cases occur in 1st pregnancy); maternal anti-A/B antibodies naturally exist from dietary/gut flora exposure | Rarely in 1st pregnancy (unless prior sensitization via transfusion, abortion, or invasive procedure); severity worsens with parity | Variable; anti-Kell is potent and can cause profound fetal anemia by suppressing erythroid progenitors |
| Direct Antiglobulin Test (DAT / Coombs) | Weakly positive (1+ to 2+) or occasionally negative (fewer A/B antigenic sites on fetal RBCs; A/B antigens expressed on other tissues) | Strongly positive (3+ to 4+); high-affinity anti-D coats all circulating D-positive RBCs | Strongly positive |
| Peripheral Blood Smear | Prominent spherocytes, polychromasia, reticulocytosis, nucleated RBCs | Marked erythroblastosis (massive nucleated RBCs), anisocytosis, reticulocytes; spherocytes rare | Anemia, reticulocytosis (or low reticulocytes in anti-Kell) |
| Clinical Severity | Typically mild to moderate; early jaundice (12–24h), mild anemia; hydrops fetalis is extremely rare | Severe to life-threatening; profound early jaundice (<12h), rapid TSB rise (> 0.5-1.0 mg/dL/hr), severe anemia, hepatosplenomegaly | Moderate to severe; anti-Kell causes severe fetal hydrops with minimal hyperbilirubinemia |
| Risk of Hydrops Fetalis | < 0.1% (virtually nonexistent) | High in untreated pregnancies (congestive heart failure, generalized anasarca, ascites, pleural effusions) | High with anti-Kell (K1) |
| Prophylactic Therapy | None available | RhoGAM (Anti-D Immune Globulin): 300 mcg at 28 weeks and within 72h postpartum | None available |
RhoGAM (Anti-D Immune Globulin) Prophylaxis Protocol
- Mechanism: RhoGAM contains high-titer human anti-D IgG. When administered to an unsensitized Rh-negative mother, it binds and clears circulating fetal Rh-positive erythrocytes from the maternal bloodstream before maternal B lymphocytes recognize the D antigen and initiate active antibody synthesis.
- Standard Dosing Schedule:
- Antepartum: One standard dose of 300 mcg (1,500 IU) IM at 28 weeks of gestation to all unsensitized Rh-negative women.
- Postpartum: One standard dose of 300 mcg IM within 72 hours of delivery if the newborn is confirmed Rh-positive and maternal antibody screen is negative.
- Antepartum Events: Administer 300 mcg after any potential fetomaternal hemorrhage event (spontaneous or induced abortion, ectopic pregnancy, amniocentesis, chorionic villus sampling, abdominal trauma, or antepartum hemorrhage). If prior to 13 weeks gestation, a micro-dose of 50 mcg may be utilized.
- Kleihauer-Betke (KB) Test: Acid-elution test that quantifies the percentage of fetal red blood cells in maternal circulation (fetal hemoglobin, HbF, resists acid elution while adult HbA elutes). One standard 300 mcg vial of RhoGAM neutralizes up to 15 mL of fetal Rh-positive red blood cells (or 30 mL of fetal whole blood). If the KB test indicates a fetomaternal hemorrhage > 30 mL, additional RhoGAM vials must be calculated and administered.
Intravenous Immunoglobulin (IVIG) Therapy
- Indication: Recommended by AAP guidelines for neonates with confirmed isoimmune hemolytic disease (ABO incompatibility, Rh disease, or minor antigens) when TSB continues to rise despite intensive phototherapy or approaches within 2 to 3 mg/dL of the exchange transfusion threshold.
- Dosing: 0.5 to 1.0 g/kg IV infused over 2 hours. A second dose may be administered 12 hours later if TSB remains elevated.
- Mechanism of Action: IVIG provides high concentrations of non-specific pooled human IgG that competitively bind and block Fc receptors on reticuloendothelial macrophages in the infant's spleen and liver. This prevents macrophages from binding, phagocytosing, and lysing antibody-coated neonatal red blood cells, halting active hemolysis and significantly reducing the need for emergent exchange transfusion.
Loading diagram...
2. Double-Volume Exchange Transfusion: Procedure & Critical Complications
Exchange transfusion is an emergent, invasive procedure designed to rapidly remove circulating antibody-coated erythrocytes, unbind circulating maternal antibodies, and clear toxic free bilirubin from the intravascular space before permanent brain damage occurs.
Clinical Indications (AAP 2022)
- Total serum bilirubin at or exceeding the hour-specific AAP exchange transfusion threshold line (stratified by gestational age and neurotoxicity risk factors).
- Total serum bilirubin rising rapidly (> 0.5 to 1.0 mg/dL/hour) despite intensive phototherapy and IVIG administration.
- Manifestation of intermediate or advanced Acute Bilirubin Encephalopathy (retrocollis, opisthotonos, shrill cry, seizures) at any TSB level.
Procedure & Volume Calculation
- Double-Volume Exchange Transfusion (DVET):
- Term Neonates: Blood Volume = 2 x (80 to 85 mL/kg) = 160 to 170 mL/kg
- Preterm Neonates: Blood Volume = 2 x (90 to 100 mL/kg) = 160 to 200 mL/kg
- Physiological Efficacy: A double-volume exchange replaces approximately 85% of circulating red blood cells and maternal antibodies, reducing serum bilirubin concentrations by 50%. Note: Serum bilirubin rebounds by approximately 20% to 30% within 2 to 4 hours as bilirubin in extravascular tissues diffuses back into the intravascular space, mandating continuous intensive phototherapy post-procedure.
- Blood Product Selection:
- Fresh packed red blood cells reconstituted with fresh frozen plasma (FFP) to achieve a target hematocrit of 45% to 50%.
- Blood must be fresh (< 5 to 7 days old) to minimize extracellular potassium concentration and maximize intracellular 2,3-DPG (ensuring optimal oxygen delivery).
- Irradiated, leukoreduced, CMV-negative, and crossmatched against maternal and neonatal serum.
- In Rh incompatibility: Rh-negative blood compatible with maternal serum.
- In ABO incompatibility: Type O blood with low anti-A and anti-B titers, compatible with maternal and infant Rh type.
Bedside Technique & Nursing Safety Bundles
- Vascular Access: Performed via an Umbilical Venous Catheter (UVC) placed in the inferior vena cava (tip at T9–T10) using an automated or manual push-pull stopcock system, or simultaneously via an Umbilical Arterial Catheter (UAC) for continuous withdrawal and UVC for continuous donor infusion.
- Aliquot Size & Rate: Exchange in small aliquots of 5 mL/kg (maximum 10 to 20 mL per cycle in term infants; 5 to 10 mL in preterm infants) over a total duration of 1.5 to 2 hours. Rapid push-pull cycles cause dangerous intracranial pressure swings and cardiac instability.
- Blood Warmer: Blood must pass through an inline blood warmer set to 37.0°C to prevent life-threatening hypothermia and cardiac arrest.
- Continuous Monitoring: Dedicated nurse monitors heart rate, continuous arterial blood pressure, ECG, oxygen saturation, and core temperature every 15 minutes.
Exchange Transfusion Complications & Nursing Protocols
+------------------------------------------------------------------------------------------------------+
| EXCHANGE TRANSFUSION COMPLICATION MATRIX |
| |
| [Citrate Anticoagulant] ──▶ Binds Ionized Calcium ──▶ HYPOCALCEMIA & Long QTc (Arrhythmias) |
| * Have 10% Calcium Gluconate (1 mL/100 mL blood exchanged) ready |
| [Stored Red Blood Cells] ──▶ Potassium Leaching ──▶ HYPERKALEMIA & Peaked T Waves / Arrest |
| * Use fresh (<5 days old), irradiated, washed donor units |
| [CPD High Dextrose] ──▶ Pancreatic Stimulation ──▶ REBOUND HYPOGLYCEMIA Post-Procedure |
| * Monitor POC glucose q30-60 min for 4 hours post-exchange |
| [Catheter Hemodynamics] ──▶ Mesenteric Swings ──▶ NECROTIZING ENTEROCOLITIS (NEC) |
| * Maintain strictly NPO during and for 24h post-exchange |
+------------------------------------------------------------------------------------------------------+
- Hypocalcemia & Citrate Toxicity: Citrate anticoagulant (CPD) in donor blood chelates ionized calcium. Monitor ionized Ca2+ and ECG for QTc prolongation. Administer 10% Calcium Gluconate (1 mL per 100 mL of blood exchanged) slowly via a peripheral IV or separate line (never infuse into the blood exchange catheter due to risk of clotting).
- Hyperkalemia: Potassium leaches from stored RBCs into donor plasma. Minimized by utilizing donor blood < 5 days old; monitor potassium post-procedure.
- Post-Exchange Hypoglycemia: The high dextrose concentration in CPD preservative stimulates fetal pancreatic insulin secretion. When the exchange concludes, abrupt cessation of glucose load triggers severe rebound hyperinsulinemic hypoglycemia. Check POC blood glucose every 30 to 60 minutes for 4 hours post-exchange.
- Thrombocytopenia: Platelet mechanical consumption during exchange; check platelet count post-procedure; transfuse platelets if < 50,000/μL.
- Necrotizing Enterocolitis (NEC): Portal venous pressure alterations and mesenteric hypoperfusion during push-pull cycles increase NEC risk. Keep infant strictly NPO during the procedure and for at least 24 hours post-exchange.
3. Neonatal Anemia: Etiologies, Assessment & PRBC Transfusion
Neonatal anemia is defined by a central venous hemoglobin or hematocrit > 2 standard deviations below the mean for gestational and postnatal age. In full-term infants at birth, a venous hemoglobin < 14.0 g/dL (or hematocrit < 42%) is diagnostic.
Etiologic Classification
- Blood Loss (Hemorrhage):
- Antepartum / Intrapartum: Fetomaternal hemorrhage (spontaneous or traumatic, diagnosed via Kleihauer-Betke test), Twin-to-Twin Transfusion Syndrome (donor twin), placenta previa, placental abruption, vasa previa, umbilical cord rupture.
- Internal Hemorrhage: Subgaleal hemorrhage (massive life-threatening scalp blood accumulation crossing suture lines), cephalhematoma, intraventricular hemorrhage (IVH), adrenal hemorrhage, subcapsular hepatic or splenic rupture.
- Iatrogenic Phlebotomy: Repeated diagnostic blood sampling in sick/preterm neonates (most common cause of hospital-acquired anemia).
- Hemolysis (Accelerated RBC Destruction):
- Isoimmune (ABO, Rh, minor blood groups Kell/Duffy/Kidd).
- RBC membrane defects (Hereditary Spherocytosis: spectrin/ankyrin gene mutations, autosomal dominant; Hereditary Elliptocytosis).
- RBC enzyme deficiencies: Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (X-linked recessive; impaired NADPH synthesis leaves RBCs vulnerable to oxidative stress from infections, maternal medications, naphthalene, or fava beans, forming Heinz bodies and bite cells); Pyruvate Kinase deficiency.
- Microangiopathic: Disseminated Intravascular Coagulation (DIC), sepsis, congenital TORCH infections (parvovirus B19 causing pure red cell aplasia, CMV).
- Decreased RBC Production (Hypoplasia):
- Anemia of Prematurity (AOP): Blunted hepatic erythropoietin (EPO) synthesis in response to tissue hypoxia, shortened RBC lifespan, and rapid somatic growth.
- Diamond-Blackfan Anemia (congenital pure red cell aplasia with thumb/craniofacial malformations).
Packed Red Blood Cell (PRBC) Transfusion Protocols
- Standard Transfusion Volume: 10 to 15 mL/kg infused slowly over 2 to 4 hours via a blood administration set with a 170- to 260-micron filter.
- Acute Exsanguinating Shock: Emergency infusion of 10 to 20 mL/kg of uncrossmatched Type O-Negative PRBCs (or 0.9% Normal Saline bolus) rapid push over 10 to 20 minutes via emergency vascular access (UVC or intraosseous).
4. Neonatal Polycythemia & Hyperviscosity Syndrome
Neonatal polycythemia is defined as a central venous hematocrit ≥ 65% (or central venous hemoglobin > 22 g/dL). Whole blood viscosity rises exponentially when hematocrit exceeds 65%, impairing microvascular capillary perfusion and causing tissue ischemia.
Critical Diagnostic Rule: Capillary vs. Venous Hematocrit
Capillary heelstick hematocrits read 5% to 15% higher than venous samples due to peripheral stasis and sludging in capillary beds. Polycythemia must never be diagnosed or treated on capillary blood alone; a central venous or arterial blood gas sample is mandatory.
Pathophysiology & Clinical Manifestations
+------------------------------------------------------------------------------------------------------+
| POLYCYTHEMIA & HYPERVISCOSITY CASCADE |
| |
| Central Venous Hct ≥65% ──▶ Exponential Surge in Blood Viscosity |
| │ |
| ▼ [Microcirculatory Sludging & Capillary Stasis] |
| Tissue Hypoperfusion ──▶ Cellular Ischemia & Microthrombi Formation |
| │ |
| ├───────────────────┬───────────────────┬───────────────────┐ |
| ▼ ▼ ▼ ▼ |
| [Neurologic] [Cardiopulmonary] [Metabolic] [Gastrointestinal/Renal] |
| * Lethargy * Tachypnea * Hypoglycemia * Feeding Intolerance |
| * Jitteriness * Cyanosis * Hyperbilirubinemia* NEC Risk |
| * Seizures / Stroke * Heart Failure * Thrombocytopenia * Oliguria / Renal Vein Thrombosis |
+------------------------------------------------------------------------------------------------------+
- Etiologies:
- Intrauterine Hypoxia: Infant of a Diabetic Mother (IDM), intrauterine growth restriction (IUGR), maternal preeclampsia/smoking, post-term gestation (> 42 weeks). Hypoxia triggers fetal renal erythropoietin (EPO) hypersecretion.
- Hypertransfusion: Delayed umbilical cord clamping (> 2 to 3 minutes), maternal-fetal transfusion, twin-to-twin transfusion syndrome (recipient twin).
- Genetic / Endocrine: Trisomies 21, 18, and 13; Beckwith-Wiedemann syndrome; congenital adrenal hyperplasia.
- Clinical Signs: Plethoric "ruddy" deep-red complexion, acrocyanosis, lethargy, poor feeding, jitteriness, tremulousness, seizures, tachypnea, priapism, oliguria, hypoglycemia (huge RBC mass consumes enormous glucose), hyperbilirubinemia (massive RBC breakdown), and thrombocytopenia (platelet consumption in microthrombi).
Partial Exchange Transfusion (PET) Protocol
- Indications: Symptomatic neonates with central venous Hct ≥ 65%, or asymptomatic neonates with central venous Hct ≥ 70%.
- Fluid Replacement: Isotonic 0.9% Normal Saline (crystalloid of choice; 5% albumin is unnecessary).
- Calculation Formula: Volume to Exchange (mL) = [Weight (kg) x Blood Volume (80-90 mL/kg) x (Observed Hct - Desired Hct 55%)] / Observed Hct
- Bedside Execution: Performed via UVC push-pull or peripheral arterial withdrawal and peripheral IV infusion in 5 mL/kg aliquots over 1 to 2 hours. Target hematocrit is 55%.
5. Neonatal Thrombocytopenia: NAIT vs. Maternal ITP
Thrombocytopenia is defined as a platelet count < 150,000/μL (mild: 100,000–150,000; moderate: 50,000–99,000; severe: < 50,000/μL; extremely severe: < 20,000/μL).
Comparison: NAIT vs. Maternal ITP
| Diagnostic Feature | Neonatal Alloimmune Thrombocytopenia (NAIT / FNAIT) | Maternal Immune Thrombocytopenic Purpura (ITP) |
|---|---|---|
| Pathophysiology | Maternal alloimmunization against paternal human platelet antigens (HPA-1a [PLA-1] in > 80%, or HPA-5b) expressed on fetal platelets | Maternal autoimmune anti-platelet IgG antibodies directed against shared maternal/fetal platelet glycoprotein IIb/IIIa |
| First Pregnancy Risk | Occurs in 50% of cases in the FIRST pregnancy (HPA antigens expressed early on syncytiotrophoblasts) | Rare in 1st pregnancy unless mother has pre-existing autoimmune disease |
| Maternal Platelet Count | COMPLETELY NORMAL (mother lacks the foreign paternal antigen) | LOW / THROMBOCYTOPENIC (maternal platelets destroyed by autoantibody) |
| Neonatal Severity | Severe to life-threatening; platelet nadir often < 20,000/μL at birth | Typically mild to moderate; platelet nadir occurs at days 2 to 5 |
| Intraventricular Hemorrhage (IVH) | High Risk (10% to 20%); 50% of IVH events occur in utero prior to delivery | Very Low Risk (< 1%); clinically significant bleeding is rare |
| Clinical Management | Emergency transfusion of washed, irradiated maternal platelets or HPA-1a/5b-negative donor platelets + IVIG (1.0 g/kg/day for 1–2 days) | Observation; platelet transfusions and/or IVIG reserved strictly for severe bleeding or count < 20,000/μL |
Test Your Knowledge
A 12-hour-old full-term infant born to a blood group O-positive mother develops visible jaundice and pallor. The infant's blood type is A-positive with a weakly positive Direct Antiglobulin Test (DAT 1+). Peripheral blood smear reveals prominent spherocytes and reticulocytosis of 12%. What is the fundamental immunological mechanism underlying this condition?
A
B
C
D
Test Your Knowledge
During a double-volume exchange transfusion via umbilical venous catheter for an infant with severe Rh isoimmunization, the bedside monitor shows a lengthening of the QTc interval on continuous ECG, followed by coarse muscle twitching and hyperreflexia. Which complication is occurring and what is the required emergency intervention?
A
B
C
D
Test Your Knowledge
A term infant weighing 3.0 kg has a routine capillary heelstick hematocrit of 72% at 4 hours of life. The infant is plethoric, tachypneic (RR 76/min), and lethargic with a blood glucose of 34 mg/dL. What is the nurse's immediate next action, and what is the calculated Partial Exchange Transfusion (PET) volume if the central venous hematocrit is confirmed at 70% (assuming a blood volume of 85 mL/kg and target Hct of 55%)?
A
B
C
D